Fig. 3

The clinical significance of the TIME phenotypes. a, b Kaplan–Meier curves for OS (a) and RFS (b) among three TIME phenotypes in the TCGA cohort. c, d Kaplan–Meier curves for OS (c) and RFS (d) among three TIME phenotypes in the NCI cohort. e Distribution of the estimated IC50 of sorafenib among three TIME phenotypes in GEO cohort. f The expression of sorafenib-related targets in three TIME phenotypes. g Distribution of the immunotherapy response results predicted by TIDE algorithm among three TIME phenotypes in the GEO cohort. h Submap analysis of the GEO cohort and 47 previous melanoma patients with detailed immunotherapeutic information. For the boxplot, the asterisks represented the statistical p value (*P < 0.05, **P < 0.01, *** P < 0.001, **** P < 0.0001)